Cadila Healthcare is currently trading at Rs. 254.15, up by 5.10 points or 2.05% from its previous closing of Rs. 249.05 on the BSE.
The scrip opened at Rs. 249.50 and has touched a high and low of Rs. 255.75 and Rs. 247.70 respectively. So far 67785 shares were traded on the counter.
The BSE group ‘A’ stock of face value Rs. 1 has touched a 52 week high of Rs. 370.00 on 03-Dec-2018 and a 52 week low of Rs. 206.45 on 22-Aug-2019.
Last one week high and low of the scrip stood at Rs. 255.75 and Rs. 230.80 respectively. The current market cap of the company is Rs. 25834.14 crore.
The promoters holding in the company stood at 74.88%, while Institutions and Non-Institutions held 17.13% and 8.00% respectively.
Zydus Cadila has received the final approval from the US Food and Drug Administration (USFDA) to market Isosorbide Dinitrate Tablets USP (US RLD-Isordil Tablet) in the strengths of 5 mg, 10 mg, 20 mg, 30 mg and 40 mg. The drug is used to prevent attacks of chest pain (angina). It dilates (widens) blood vessels, making it easier for blood to flow through them and easier for the heart to pump. It will be manufactured at the group’s formulations manufacturing facility at Baddi.
The group also received the final approval for Desonide Cream (US RLD-Desonide Cream), 0.05%. The drug is a mild corticosteroid, used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash) to reduce swelling, itching and redness that can occur in these types of conditions. It will be manufactured at the group’s Topical manufacturing facility at Ahmedabad.
The group now has 278 approvals and has so far filed over 330 ANDAs since the commencement of the filing process in FY 2003-04.
Cadila Healthcare is an India-based pharmaceutical company. The company’s subsidiaries include Zydus Wellness, Liva Pharmaceuticals, Biochem Pharmaceutical Industries, Zydus Technologies, German Remedies, Dialforhealth India, Dialforhealth Unity and Dialforhealth Greencross, among others.